1. Home
  2. TRX vs CLLS Comparison

TRX vs CLLS Comparison

Compare TRX & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TRX Gold Corporation

TRX

TRX Gold Corporation

HOLD

Current Price

$1.29

Market Cap

403.8M

Sector

N/A

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$4.11

Market Cap

384.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRX
CLLS
Founded
1990
1999
Country
Canada
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
403.8M
384.3M
IPO Year
2002
2014

Fundamental Metrics

Financial Performance
Metric
TRX
CLLS
Price
$1.29
$4.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$1.70
$8.33
AVG Volume (30 Days)
3.8M
27.9K
Earning Date
04-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$84.84
N/A
Revenue Next Year
$96.90
$0.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.32
$1.33
52 Week High
$2.80
$5.48

Technical Indicators

Market Signals
Indicator
TRX
CLLS
Relative Strength Index (RSI) 49.45 52.20
Support Level $1.23 $3.39
Resistance Level $2.00 $4.48
Average True Range (ATR) 0.08 0.18
MACD 0.02 -0.02
Stochastic Oscillator 79.31 54.35

Price Performance

Historical Comparison
TRX
CLLS

About TRX TRX Gold Corporation

TRX Gold Corp is engaged in the exploration, development, and production of mineral property interests in the United Republic of Tanzania, focused on development and mining operations, and on exploring and evaluating its mineral properties. The business of exploring and mining for minerals involves a high degree of risk, and the underlying value of the mineral properties depends on the existence and economic recovery of mineral resources and reserves, as well as the ability to raise long-term financing to continue development. The company is focused on the Buckreef Gold Project, which comprises five prospects: Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba, and includes three main mineralized zones: Buckreef South, Buckreef Main, and Buckreef North.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: